A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)

Phase 3

AfliberceptA Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)

Sponsor:

Bayer

Code:

NCT05850520

Conditions

Macular Edema Secondary to Retinal Vein Occlusion

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose

Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg

Sham

Fluorescein

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-16. This information was provided to ClinicalTrials.gov by Bayer on 2025-05-04.